ClinConnect ClinConnect Logo
Search / Trial NCT04609072

Connect for Cancer Prevention Study (Connect)

Launched by NATIONAL CANCER INSTITUTE (NCI) · Oct 29, 2020

Trial Information

Current as of June 21, 2025

Recruiting

Keywords

Risk Factors Medical Conditions Pathology Blood Urine Natural History

ClinConnect Summary

The Connect for Cancer Prevention Study is a large research project aimed at understanding the causes of cancer and finding new ways to prevent it. Researchers want to learn how our lifestyle, genetics, and health history can influence cancer risk. This study is open to 200,000 adults aged 30 to 70 who are receiving health care from one of the participating health systems and have never had cancer (though those with a history of non-melanoma skin cancer or certain conditions that may increase cancer risk can still join).

If you choose to participate, you can sign up online and will need to complete an informed consent process to ensure you understand what the study involves. Participants will answer health surveys a few times a year and provide samples of blood, urine, and saliva every two to three years. You may also share information from health trackers, like fitness apps. The study will last for many years, allowing researchers to gather valuable information, and you can decide to leave the study at any time. For more information, you can visit cancer.gov/connectstudy.

Gender

ALL

Eligibility criteria

  • * INCLUSION CRITERIA:
  • Due to the minimal risk nature of this protocol, all individuals interested and able to participate in Connect for Cancer Prevention, who meet the eligibility criteria at time of initial study invitation, will be able to participate. In order to be eligible to participate in this study, an individual must meet all of the following criteria:
  • Patients or members of participating IHCS at the time of enrollment
  • Age between 30 and 70 years old at study invitation
  • If an individual is determined to be ineligible at the time of enrollment due to age, the individual will be allowed to re-enroll at a later time once the recruit meets the age requirement. This includes recruits that did not meet the original age requirement of 40-65 years of age but now meet the updated age range of 30-70.
  • EXCLUSION CRITERIA:
  • An individual who meets any of the following criteria at time of initial study invitation will be excluded from participation in this study:
  • Individuals with a confirmed history of invasive cancer (other than non-melanoma skin cancer)
  • Individuals with known cognitive impairment documented in their medical record

About National Cancer Institute (Nci)

The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.

Locations

Detroit, Michigan, United States

Chicago, Illinois, United States

Atlanta, Georgia, United States

Sioux Falls, South Dakota, United States

Chicago, Illinois, United States

Minneapolis, Minnesota, United States

Marshfield, Wisconsin, United States

Dallas, Texas, United States

Denver, Colorado, United States

Honolulu, Hawaii, United States

Chicago, Illinois, United States

Bethesda, Maryland, United States

Portland, Oregon, United States

Patients applied

0 patients applied

Trial Officials

Nicolas A Wentzensen, M.D.

Principal Investigator

National Cancer Institute (NCI)

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials